Mode
Text Size
Log in / Sign up
Phase 4 N=97 Randomized Prevention

Bowel Function After Minimally Invasive Hysterectomy

Constipation

Enrolled (actual)
97
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM) Score — 1.1; 0.6 score

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Polyethylene Glycol 3350 (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of Chicago
Primary completion
Jun 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM) Score
1.1; 0.6
PRIMARY
Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) Score
8.4; 10; 21.6; 16.5
SECONDARY
Visual Analog Scale for Pain Management
5.807692; 5.934615; 5.114815; 5.516; 4.572; 4.681481
SECONDARY
Pain Medication Consumption Tracking by Participant
11.82692; 14.33333; 8.981481; 12.58333; 7.410714; 7.758621
SECONDARY
Wexner/ Constipation Scoring System/1996 Cleveland Clinic Score / Agachan Score
7.3; 5.6

Summary

Postoperative constipation affects up to a third of women undergoing minimally invasive (MIS) gynecologic surgery and is a major source of anxiety and discomfort. The average time to first bowel movement after gynecologic surgery is about 2 to 4 days and some factors responsible for this include anesthesia inhibitory effect on gastrointestinal motility, opioid pain medication use, chronic nonsteroidal anti-inflammatory drugs (NSAID) use and anatomic manipulation. There are no established regimens to manage postoperative constipation after minimally invasive gynecologic surgery. Two studies evaluating the implementation of postoperative bowel regimen with polyethylene glycol (PEG) and with Senna and Docusate found no significant impact on postoperative bowel function. There have been no studies looking at the effect of preoperative bowel regimens on postoperative bowel function. The purpose of this study is to evaluate postoperative bowel function after minimally invasive hysterectomy in women receiving a preoperative 10-day bowel regimen of PEG daily.

Eligibility Criteria

Inclusion Criteria

  • Any woman ≥ 18 years of age undergoing a minimally invasive hysterectomy (Laparoscopic, robotic, vaginal)
  • Able to understand the consenting process and willing to participate in study

Exclusion Criteria

  • Planned laparotomy
  • Emergent surgery
  • Regular preoperative use of PEG 3350, laxatives, enemas or suppositories
  • Planned bowel surgery
  • Presence of colostomy
  • Inability to consent
  • Medical problems as follows:
  • Chronic Kidney Disease (Cr: > 1.2 mg/dL)
  • Insulin-Dependent Diabetes Mellitus
  • Cardiac disease
  • Gastric ulcers
  • Difficulty swallowing or esophageal stricture
  • Persistent nausea or vomiting
  • Signs or symptoms of a small bowel obstruction
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04263896). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search